Novocure Ltd (NVCR)

Currency in USD
12.17
+0.87(+7.70%)
Closed·
12.170.00(0.00%)
·
Earnings results expected in 14 days
NVCR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
11.3012.44
52 wk Range
9.8220.06
Key Statistics
Prev. Close
11.3
Open
11.3
Day's Range
11.3-12.44
52 wk Range
9.82-20.06
Volume
2.02M
Average Vol. (3m)
1.88M
1-Year Change
-23.1207%
Book Value / Share
3.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NVCR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.07
Upside
+106.01%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings downwards for the upcoming period

Novocure Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Novocure Ltd SWOT Analysis


Market Expansion Horizon
Novocure targets new oncology markets with $38 price target, balancing innovation against adoption challenges and R&D investments
Patient-Centric Advances
FDA approval of Head Flexible Electrode arrays aims to enhance comfort and compliance, potentially boosting treatment efficacy and revenue
Clinical Breakthroughs
PANOVA-3 trial results reveal significant survival benefits for pancreatic cancer patients, potentially opening new market opportunities
Innovative Cancer Tech
Novocure's TTFields therapy disrupts cancer cell division, showing promise in treating aggressive tumors like glioblastoma multiforme
Read full SWOT analysis

Novocure Ltd Earnings Call Summary for Q4/2024

  • Q4 revenue of $161M exceeded forecasts, up 21% YoY, despite EPS miss of -$0.61 vs -$0.36 expected
  • Full year 2024 revenue reached $605M, a 19% increase, with strong international growth and $960M cash on hand
  • Company expects low to mid-single digit growth in GBM business for 2025, with significant revenue ramp from lung cancer in 2026
  • Novocure aims for positive adjusted EBITDA as new indication revenues materialize, expanding beyond single GBM focus
  • Stock showed resilience with minor premarket decline; analysts maintain positive outlook despite ongoing profitability challenges
Last Updated: 02/27/2025, 09:12 AM
Read Full Transcript

Compare NVCR to Peers and Sector

Metrics to compare
NVCR
Peers
Sector
Relationship
P/E Ratio
−10.2x−3.6x−0.5x
PEG Ratio
−0.46−0.120.00
Price / Book
4.1x4.0x2.6x
Price / LTM Sales
2.1x5.0x3.2x
Upside (Analyst Target)
108.5%54.1%45.7%
Fair Value Upside
Unlock8.6%4.8%Unlock

Analyst Ratings

5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 25.07
(+106.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Evercore ISI
Buy16.00+31.47%23.00MaintainApr 06, 2026
H.C. Wainwright
Buy47.00+286.20%39.00MaintainFeb 12, 2026
Piper Sandler
Buy27.00+121.86%-MaintainJan 30, 2026
H.C. Wainwright
Buy39.00+220.46%-MaintainJan 13, 2026
Wells Fargo
Hold13.50+10.93%14.50MaintainDec 12, 2025

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-0.22 / -0.41
Revenue / Forecast
174.35M / 168.31M
EPS Revisions
Last 90 days

NVCR Income Statement

People Also Watch

7.78
IBRX
+2.37%
13.030
RCAT
+3.09%
308.20
COHR
-1.67%
238.42
BWXT
+0.06%

FAQ

What Is the Novocure Ltd (NVCR) Stock Price Today?

The Novocure Ltd stock price today is 12.17 USD.

What Stock Exchange Does Novocure Ltd Trade On?

Novocure Ltd is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Novocure Ltd?

The stock symbol for Novocure Ltd is "NVCR."

What Is the Novocure Ltd Market Cap?

As of today, Novocure Ltd market cap is 1.39B USD.

What Is Novocure Ltd's Earnings Per Share (TTM)?

The Novocure Ltd EPS (TTM) is -1.22.

When Is the Next Novocure Ltd Earnings Date?

Novocure Ltd will release its next earnings report on Apr 30, 2026.

From a Technical Analysis Perspective, Is NVCR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Novocure Ltd Stock Split?

Novocure Ltd has split 0 times.

How Many Employees Does Novocure Ltd Have?

Novocure Ltd has 1605 employees.

What is the current trading status of Novocure Ltd (NVCR)?

As of Apr 16, 2026, Novocure Ltd (NVCR) is trading at a price of 12.17 USD, with a previous close of 11.30 USD. The stock has fluctuated within a day range of 11.30 USD to 12.44 USD, while its 52-week range spans from 9.82 USD to 20.06 USD.

What Is Novocure Ltd (NVCR) Price Target According to Analysts?

The average 12-month price target for Novocure Ltd is 25.07 USD, with a high estimate of 49 USD and a low estimate of 13.5 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +106.01% Upside potential.

What Is the NVCR Premarket Price?

NVCR's last pre-market stock price is 11.26 USD. The pre-market share volume is 570.00, and the stock has decreased by -0.04, or -0.35%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.